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Abstract
Background: The incidence rate of pulmonary emboli (PE) is high in tumor patients; however, the morbidity and
mortality associated with the development of PE after tumor surgery are unknown. We studied the clinical profiles
and outcomes of patients with PE after non-brain tumor surgery.
Methods: We retrospectively screened 55,967 patients who underwent non-brain tumor surgery at the Peking
University Cancer Hospital from January 2008 to June 2015. Among them, 76 patients who were diagnosed with
PE were enrolled in our study. Factors impacting the overall survival at 90 days were analyzed. A Kaplan-Meier
curve was plotted for time to death or until day 90. Cox proportional hazard modeling was performed for
univariate- and multivariate-adjusted factor analyses.
Results: The morbidity rate was approximately 135.8 per 100,000 non-brain tumor surgery patients (possibly
underestimated). When treated, seven patients had major bleeding, and 14 patients had clinically relevant
non-major bleeding, which represented 9.2 and 18.4% of all the patients, respectively. The 3-month overall
mortality rate was 11.8% in our study. The Acute Physiology and Chronic Health Evaluation II (APACHE II)
score and platelet distribution width (PDW) were independent risk factors for the prognosis of PE after non-
brain surgery (P values of 0.001 and 0.016, respectively).
Conclusions: Treatment of PE in non-brain tumor surgical patients remained a challenge due to the high
bleeding rate. The APACHE II score and PDW were independent prognostic factors of survival in patients
with PE after non-brain tumor surgery; however, the study power was limited.
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Background
Venous thromboembolism (VTE) includes deep vein
thrombosis (DVT) and pulmonary embolism (PE).
Pulmonary emboli account for an increasing proportion
of venous thromboemboli with increasing patient age.
Venous thromboembolism is the third most common
cardiovascular disease [1, 2]. There are approximately
300,000–600,000 cases per year in the USA, resulting in
60,000–100,000 deaths each year [3]. Pulmonary
embolism-related deaths in the USA may exceed
myocardial infarction-related and stroke-related deaths
[4]. Although less common in certain regions, such as
Asia, venous thromboembolism is a worldwide problem,
particularly in people with known risk factors [5, 6]. In
China, the overall annual incidence of PE is 3.9 per
100,000 individuals and the hospital mortality rate associ-
ated with PE is 23.8% [5].
Surgery and malignancy increase the risk of VTE
[7, 8]. The risk of VTE increases over 90-fold during
the first 6 weeks after cancer surgery, compared with
that observed in healthy controls, and is second only
to the risk of VTE after hip or knee replacement sur-
gery [9]. The risk of venous thrombosis in cancer
patients depends on the tumor type and stage, treatment
* Correspondence: doctorwhz@163.com
Critical Care Medicine, Key Laboratory of Carcinogenesis and Translational
Research (Ministry of Education), Peking University Cancer Hospital and
Institute, Beijing 100142, China
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chen et al. World Journal of Surgical Oncology  (2017) 15:22 
DOI 10.1186/s12957-016-1074-3
measures, and patient-associated factors [10]. The mecha-
nisms may involve mucin production by tumors, exposure
of tissue factor-rich surfaces and tissue factor-bearing
microparticles, cysteine proteinase production leading to
thrombin generation, and local hypoxia [11, 12].
However, previous studies have not analyzed patients
according to their status, e.g., medical or surgery
patients. Because of the high risk of bleeding, therapy
for patients with PE after surgery is different from med-
ical patients. The aim of this study was to explore the




From January 2008 to June 2015, 55,967 patients who
underwent surgery for the treatment of tumors at the
Peking University Cancer Hospital were retrospectively
screened. The diagnosis of PE was made according to
the American College of Chest Physicians, ninth edition
(ACCP 9th Ed.) guidelines. A total of 76 cases were
included for analysis in our study.
Definitions
Patients who underwent fibrinolysis received a single
weight-based intravenous administration (over a period
of 2 h) of the fibrinolytic agent urokinase.
Those patients were administered nadroparin calcium
first. We defined adequate anticoagulation treatment as
the dose of nadroparin calcium for 0.08–0.1 mL/10 kg,
every 12h (q12h), and reduced anticoagulation treatment
as less than 0.08 mL/10 kg, q12h.
Bleeding was considered major if it was clinically overt
and associated with a decrease of 2 g per deciliter (or
more) according to the hemoglobin level, led to the
transfusion of 2 or more units of red blood cells, was
retroperitoneal or intracranial, occurred in a critical
organ, or contributed to death. Bleeding episodes that
were clinically relevant but did not qualify as major (e.g.,
epistaxis that required intervention, formation of a large
hematoma visible on the skin, or spontaneous macro-
scopic hematuria) were classified as clinically relevant
non-major bleeding.
Statistical analyses
Values are expressed as the means (ranges) unless other-
wise stated. The effect of factors influencing the overall
survival at 90 days was analyzed. A Kaplan-Meier curve
was plotted for time to death or until day 90. Cox pro-
portional hazard modeling was performed for univariate-
and multivariate-adjusted factor analyses. The forward
stepwise method was applied during the multivariate
analysis. Statistical analyses were performed using SPSS




Seventy-two patients were diagnosed with PE by com-
puted tomographic pulmonary angiography (CTPA).
Two patients were diagnosed via positive compression
venous ultrasonography with decreased peripheral blood
oxygen saturation because CTPA was unsafe for these
patients. Two patients died quickly in the general ward
(making an examination impossible). In these patients,
PE was diagnosed via clinicians with expert clinical ex-
perience. The main baseline characteristics of the in-
cluded patients are presented in Table 1. The clinical
presentations and diagnoses of the included patients are
listed in Table 2.
Treatment, bleeding, and recurrence
All the patients were provided mechanical prophylaxis
after surgery. However, only 16 patients received
prophylactic anticoagulation drugs before the diagnosis
Table 1 Patients with PE
Items Results
Age, years (mean ± SD) 64.1 ± 10.1
Male/female (number) 34/42
BMI, kg/m2 (mean ± SD) 26.0 ± 3.5
Tumor (number)
Breast cancer 20
Digestive system cancera 33
Thoracic tumorb 18










Surgery incision infection 1
ICU admission (number) 56
Hemoglobin before surgery, g/L (mean ± SD) 131.4 ± 18.1
PE pulmonary embolism, BMI body mass index, SD standard deviation
aIncluding 4 cases of esophageal cancer, 12 cases of gastric cancer, 10 cases
of colorectal cancer, 4 cases of liver cancer, 2 cases of pancreatic cancer, and 1
case of primary peritoneal carcinoma
bIncluding 13 cases of lung cancer, 4 cases of benign lung tumors, and 1 case
of thymoma
cIncluding two cases of endometrial carcinoma, one case of ovarian cancer,
and one case of uterine cancer
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of PE. Every patient was provided oxygen after the diag-
nosis of PE. Among them, six cases underwent tracheal
intubation ventilator-assisted breathing; four cases used
non-invasive ventilator-assisted breathing initially (and
two cases improved); the other two patients finally
advanced to tracheal intubation ventilator-assisted
breathing.
In this group, two patients did not receive any anti-
coagulant or thrombolytic agents, and two patients were
administered urokinase (20,000 U/kg of body weight) for
intravenous thrombolysis within 2 h. Sequentially, the
patients were administered nadroparin calcium. Among
the patients who used anticoagulants as an initial ther-
apy, one patient received fondaparinux because of
heparin-induced thrombocytopenia (HIT) after the
prevention of anticoagulant therapy with nadroparin
calcium, and the others were initially administered
nadroparin calcium. Because of the high risk of bleeding
after surgery, more than half of the patients in this group
received a reduced dosage of anticoagulant therapy.
Thereafter, 33 patients were transitioned to warfarin
by mouth or nutrient line when permitted. The inter-
national normalized ratio (INR) was monitored. When
the INR reached 2.0 or higher for at least 24 h, unfrac-
tionated heparin or nadroparin calcium was discontin-
ued. Forty patients continued to use nadroparin calcium
as anticoagulation therapy, and one patient used
fondaparinux.
The frequency of bleeding is listed in Table 3. During
the course of treatment, seven patients experienced
major bleeding. Therefore, two patients stopped anticoa-
gulation therapy and five patients decreased the dosage
of anticoagulation therapy and were administered a
blood transfusion. A total of 14 patients experienced
clinically relevant non-major bleeding and were adjusted
to a reduced dosage of anticoagulation therapy. Ultim-
ately, all patients stopped bleeding.
Five cases experienced a recurrence of VTE within
3 months. Among them, two cases were administered
the intravenous thrombolytic agent urokinase as a re-
medial treatment and three cases received unfractio-
nated heparin. At the same time, one patient received an
inferior vena cava filter after the recurrence of VTE.
Survival analysis
The patients were followed up for 3 months, and no
patients were lost to follow-up. The 3-month mortality
rate was 11.8% (9/76). Survival curves are shown in
Fig. 1. Age, body mass index (BMI), Acute Physiology
and Chronic Health Evaluation II (APACHE II) score,
platelet distribution width (PDW), and mean platelet
volume divided by platelet (MPV/PLT) were analyzed in
the multiple Cox regression analysis. The APACHE II
score and PDW were independent risk factors for the
prognosis of PE after surgery, and the relative risk values
were 1.229 and 1.840, respectively (Table 4). The
area under the curve (AUC) of the APACHE II
scores according to the Receiver Operating Charac-
teristic (ROC) curve was 0.923. If the cutoff APA-
CHE II score was 12, the sensitivity was 1 and the
specificity was 0.716. The AUC of PDW according to the
Table 2 Diagnosis of PE

















PCO2 < 35 mmHg 12
PO2/FiO2 ≤ 300 mmHg 57
Lac≥ 2 mmol/L 19
D-Dimer elevated 63
Pulmonary artery hypertensiond 3
Positive troponine 2
Compression venous ultrasonographyf
Lower extremity venous thrombosis 32
Internal jugular and subclavian vein thrombosis 3
APACHE II score > 15 13
APACHE II score Acute Physiology and Chronic Health Evaluation II score
aSome patients had more than one symptom
bData were available for 59 patients
cData were available for 68 patients
dData were available for 24 patients
eData were available for 60 patients
fData were available for 70 patients
Table 3 Treatment and bleeding
Initial therapy (numbers) Major bleeding Clinically relevant
non-major bleeding
Thrombolysis (2) 1 0
Adequate anticoagulation (31) 1 5
Reduced anticoagulation (41) 5 9
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ROC curve was 0.706. If the cutoff PDW was 12.4, the
sensitivity was 0.778 and the specificity was 0.642.
Discussion
The morbidity rate of PE was approximately 135.8 per
100,000 patients in our study. In this study, digestive
system cancer (43.4%) accounted for the largest propor-
tion, followed by breast cancer (26.3%). These tumors
are the most common tumors in our hospital. There
were no patients with PE after orthopedic surgery in our
hospital during the study years, which might be attrib-
uted to positive preventive anticoagulation. The clinical
signs and symptoms of PE were non-specific. PE should
be suspected based on dyspnea, chest pain, pre-syncope,
syncope, and/or hemoptysis. Arterial hypotension and
shock were rare but important clinical presentations
because they indicated a severely reduced hemodynamic
reserve [13]. In our study, dyspnea was the most com-
mon presenting symptom, observed in 65.8% of the
patients, followed by a lack of symptoms with decreasing
oxygen saturation.
In our study, 72 patients were diagnosed by computed
tomographic pulmonary angiography; the other 4
patients could not be safely transported for CTPA. Com-
puted tomographic pulmonary angiography seems to be
the most useful method for the diagnosis of PE in critic-
ally ill patients. For patients who are so critically ill that
transport is unsafe or unfeasible, thrombolytic therapy
should be considered if there are clear signs of right
ventricular overload according to bedside echocardiog-
raphy [14]. A positive result on a lower extremity
Doppler ultrasound can also be a great help in the deci-
sion for treatment.
The choice of treatment for PE depends on the
estimated risk of poor outcome. The presence of
hypotension is the most significant predictor of poor
outcome and is common in patients with massive
PE. Currently, in patients with acute PE associated
with hypotension who do not have a high risk of
bleeding, systemically administered thrombolytic
therapy is proposed [15]. For patients with a contra-
indication to anticoagulation and thrombolytic
therapy, surgical embolectomy and catheter-based
therapies are options. However, the role of inferior
vena cava filters, catheter-based interventions, and
surgical embolectomy in life-threatening PE has not
yet been absolutely defined. Muriel et al. reported
that in patients presenting with VTE and a signifi-
cant bleeding risk, inferior vena cava filter insertion
was associated with a lower risk of PE-related death
and a higher risk of recurrent VTE (compared with
anticoagulant therapy) [16].
Normotensive patients with evidence of right ventricu-
lar (RV) dysfunction as assessed by echocardiography
comprise the sub-massive category and have an inter-
mediate risk of poor outcomes. Clinically, patients with
sub-massive PE are difficult to distinguish from patients
with low-risk PE. Some studies reported that cardiac
troponin and brain natriuretic peptide could raise the
suspicion that a patient had sub-massive PE [17–19].
The role of fibrinolytic therapy in patients with
intermediate-risk PE is controversial. According to one
study [20], in patients with intermediate-risk PE, fibrino-
lytic therapy could reduce early death but increases the
Fig. 1 Kaplan-Meier survival curve of overall survival at 90 days
Table 4 Cox regression analysis
RR 95% CI P value
APACHE II score 1.229 1.127–1.341 0.001
PDW 1.840 1.118–3.027 0.016
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risk of major bleeding and stroke. During recent years,
echocardiography and brain natriuretic peptide (BNP)
have not been examined routinely in our hospital. Many
data were missing, and we could not stratify non-high-
risk PE patients into intermediate-risk and low-risk PE
patients. However, this did not influence our treatment
of those patients. All patients initially received anticoa-
gulation therapy.
Anticoagulation is the foundation therapy for PE.
Low-molecular-weight heparins and fondaparinux were
preferred over unfractionated heparin due to their
usability [21–23]. All patients with PE in our study had a
high risk of bleeding after surgery. We should consider
the balance of bleeding risk versus benefit for each
patient. However, there was no compelling evidence to
validate a scoring system to predict the bleeding risk for
patients with VTE. Seven patients experienced major
bleeding, and 14 patients experienced clinically relevant
non-major bleeding, which accounted for 9.2 and 18.4%
of all patients, respectively. This rate is higher than other
reports. As stated above, all patients stopped bleeding
via conservative therapy and no bleeding-related deaths
occurred.
The 3-month overall mortality rate was previously
reported to be approximately 15 to 18% [24]; the values
found in our study were lower. Shock upon presentation
was associated with an increase in mortality by a factor
of 3–7 [24]. Naess et al. reported that secondary cancer
VTE is associated with increased mortality relative to
secondary non-cancer VTE and idiopathic VTE [25].
According to a study by Yardan et al. [26], a high MPV/
PLT ratio is associated with RV dysfunction and clinical
severity in patients with acute PE and a low MPV/PLT
level might be an indicator of low bleeding risk in
patients with acute PE. In our study, the APACHE II
score and PDW were independent prognostic factors of
survival (but not MPV/PLT). The total number of
patients in our study was limited, and further research is
needed.
The risk of recurrence was particularly high among
patients with cancer [14]. The probability of recurrent
thromboembolism at 6 months was 17% in the oral-
anticoagulant group and 9% in the low-molecular-weight
heparin group [27]. The recurrence rate of VTE was
approximately 6.5% within 90 days in our study. Two
patients died after VTE recurrence. In the recurrent
patients, two cases received intravenous unfractionated
heparin for the treatment of PE and they ultimately
survived. This therapy provides another option for
patients with recurrence; however, more studies are
needed to support this treatment course.
Prophylaxis remained underutilized in patients who
were admitted to the hospital with a moderate or high
risk of venous thromboembolism and was probably due
to the concern regarding the risk of bleeding. We should
propose guidelines for the prophylaxis and management
of PE after surgery. More active education is required to
raise awareness and to ensure the implementation of
these guidelines, which may reduce the burden of PE in
patients with tumors after surgery. For patients with a
high risk of VTE who are undergoing abdominal or
pelvic surgery for cancer, the ACCP 9th Ed. guidelines
recommend extended-duration, postoperative, pharma-
cologic prophylaxis (4 weeks) with LMWH (in contrast
to limited-duration prophylaxis) [15].
Currently, the USA has approved one direct thrombin
inhibitor (dabigatran) and three factor Xa inhibitors
(apixaban, rivaroxaban, and edoxaban) for the treatment
of acute VTE. In a series of important studies, each of
these agents has been demonstrated to be at least as safe
and effective for the treatment of acute VTE as the trad-
itional bridging strategy (parenteral anticoagulation/war-
farin) [28–31]. These drugs do not require any
coagulation monitoring in the laboratory and may be
accepted by most people in the future.
Several limitations should be mentioned. First, this
study was a retrospective study. A prospective study
with a control group consisting of patients with PE with-
out tumors and without operations may be more useful.
Second, many data were missing, especially data regard-
ing ultrasound cardiogram (UCG). Third, the prevalence
of PE may have been underestimated because no autop-
sies were performed and not all patients underwent
CTPA. Finally, the sample size in our COX analysis was
small, increasing the risk of a type 2 error due to a lack
of statistical power. Larger studies are needed to address
the challenging issues during the treatment of tumor
surgical patients with PE.
Conclusions
The treatment of PE in surgical patients with tumors re-
mains a clinical challenge due to the high bleeding rate.
The APACHE II score and PDW were independent
prognostic factors of survival in patients with PE after
non-brain surgery; however, the statistical power was
limited.
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